BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Clinical safety rating: avoid
Live vaccines should not be given concurrently Phenytoin phenobarbital and rifampin reduce corticosteroid effects Systemic effects can occur with extensive topical use.
Betamethasone acetate and betamethasone sodium phosphate are corticosteroids that bind to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as prostaglandins and leukotrienes. They inhibit phospholipase A2, reduce cytokine production, and decrease immune cell migration and activation.
| Metabolism | Primarily hepatic via CYP3A4; also metabolized by 11β-hydroxysteroid dehydrogenase. Metabolites include 6β-hydroxybetamethasone and other polar metabolites, which are excreted renally. |
| Excretion | Betamethasone and its metabolites are excreted primarily in urine (80-90%), with less than 10% in feces via biliary excretion. Approximately 25% is excreted unchanged. Renal clearance involves glomerular filtration and tubular reabsorption. |
| Half-life | The terminal elimination half-life of betamethasone is approximately 6.5 hours (range 4-8 hours) in plasma. This corresponds to a biological half-life of 36-54 hours for anti-inflammatory effects due to receptor occupancy and downstream effects. Clinical dosing intervals are typically 12-24 hours for sustained effect. |
| Protein binding | 64% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG, transcortin). Binding is saturable at high doses. |
| Volume of Distribution | Volume of distribution is 1.4 L/kg (range 1.0-1.8 L/kg). This large Vd indicates extensive tissue distribution, including penetration into cerebrospinal fluid, synovial fluid, and placenta. |
| Bioavailability | Oral: approximately 100% (well-absorbed); IM (sodium phosphate): 100% (rapid absorption); IM (acetate): slow absorption, bioavailability 100% but prolonged; Topical: 1-5% (depends on site, inflammation, and vehicle). |
| Onset of Action | Intravenous (IV): 0.5-1 hour; Intramuscular (IM): 1-3 hours; Oral: 1-2 hours; Topical: hours to days (depends on formulation and skin condition). For respiratory indications (e.g., croup), clinical effect may be seen within 2-6 hours. |
| Duration of Action | Duration of adrenal suppression: up to 48-72 hours after a single dose; anti-inflammatory effect persists 24-36 hours. For respiratory efficacy, measurable improvement lasts 12-24 hours. After intramuscular administration, action can persist 1-3 weeks due to delayed absorption from acetate ester. Clinical note: Betamethasone acetate is a long-acting ester for depot preparations. |
| Molecular Weight | Betamethasone acetate: 434.5 Da; Betamethasone sodium phosphate: 516.4 Da |
1-4 mg (of betamethasone base) IM or IV every 12-24 hours, tapering as clinically indicated.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required due to minimal renal elimination; use with caution in severe renal impairment. |
| Liver impairment | In Child-Pugh Class B or C, consider a 50% dose reduction or increase dosing interval; titrate to lowest effective dose. |
| Pediatric use | 0.02-0.3 mg/kg/day IM or IV in divided doses every 6-12 hours, with maximum initial dose of 1.5 mg/kg/day. |
| Geriatric use | Initiate at lowest effective dose; consider dose reduction of 30-50% to minimize osteoporosis, hyperglycemia, and immunosuppression risks. |
| 1st trimester | Use only if clearly needed. Corticosteroids are associated with increased risk of cleft palate in animal studies; human data limited. Consider risk-benefit. |
| 2nd trimester | Use only if clearly needed. Potential for fetal growth restriction and adrenal suppression. Monitor fetal growth. |
| 3rd trimester | Use with caution; may cause fetal adrenal suppression. Avoid prolonged use. If used near term, monitor neonate for hypoadrenalism. |
Clinical note
Live vaccines should not be given concurrently Phenytoin phenobarbital and rifampin reduce corticosteroid effects Systemic effects can occur with extensive topical use.
| FDA category | Positive |
| Placental transfer | Betamethasone crosses the placenta. The acetate and phosphate forms are converted to active betamethasone. Placental metabolism partially reduces fetal exposure, but biologically active drug reaches fetus. Used therapeutically for fetal lung maturation. |
■ FDA Black Box Warning
None officially. However, long-term use may lead to adrenal suppression, and abrupt withdrawal can cause acute adrenal insufficiency. Intra-articular injection may cause joint instability or infection.
| Common Effects | Hyperglycemia |
| Serious Effects |
Systemic fungal infectionHypersensitivity to betamethasone or any componentIntrathecal administration (due to risk of arachnoiditis)Live or live-attenuated vaccines (concurrent use)
| Precautions | Adrenal suppression: Prolonged use may suppress HPA axis; taper dose gradually., Immunosuppression: Increased risk of infections; avoid live vaccines., Osteoporosis: Long-term use increases fracture risk; monitor bone density., Hyperglycemia: May exacerbate diabetes; monitor blood glucose., Gastrointestinal perforation: Risk in patients with ulcerative colitis, diverticulitis, or recent GI surgery., Ocular effects: Cataracts, glaucoma; monitor intraocular pressure., Psychiatric disturbances: May cause euphoria, insomnia, mood swings, or psychosis., Growth suppression in children: Monitor growth in pediatric patients., Cushing's syndrome: With high doses or prolonged use., Electrolyte disturbances: Hypernatremia, hypokalemia, fluid retention; monitor electrolytes. |
Loading safety data…
| Breastfeeding | Betamethasone is excreted into breast milk in small amounts. At maternal doses up to 8 mg/day, amounts are unlikely to affect the infant. However, with high doses or prolonged use, monitor infant for adrenal suppression. Use lowest effective dose for shortest duration. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | First trimester: Increased risk of cleft lip/palate (OR 1.3-3.3). Second/third trimester: Fetal adrenal suppression, growth restriction, oligohydramnios with prolonged use. Corticosteroids cross placenta; betamethasone is partially inactivated by 11β-HSD2 but still achieves fetal concentrations ~30% of maternal. |
| Fetal Monitoring | Maternal: Blood pressure, blood glucose, signs of infection, adrenal suppression with long-term use. Fetal/neonatal: Ultrasound for growth restriction and amniotic fluid volume with repeated doses; neonatal monitoring for adrenal suppression if maternal treatment continues until delivery. |
| Fertility Effects | No known direct effect on fertility. High doses may disrupt menstrual cycle secondary to hypothalamic-pituitary-adrenal axis suppression. Theoretical risk of delayed ovulation or luteal phase defects. |
| Food/Dietary | No significant food-drug interactions. Avoid excessive sodium intake if fluid retention occurs. Limit alcohol consumption to minimize risk of GI bleeding and osteoporosis. Monitor potassium intake if hypokalemia develops. No specific dietary restrictions required for single or intermittent doses. |
| Clinical Pearls | Betamethasone acetate is a long-acting ester for sustained release; betamethasone sodium phosphate is a rapid-acting soluble salt. Onset of action within 1 hour; duration up to 7 days. Not for IV or IM administration (only for intra-articular, intralesional, or soft tissue injection). Avoid injection into infected joints or unstable joints. Do not administer intrathecally (risk of arachnoiditis). Use the smallest effective dose and shortest duration. Taper dose when discontinuing after prolonged use. Monitor for adrenal suppression, osteoporosis, and hyperglycemia. Contraindicated in systemic fungal infections and live vaccine administration. |
| Patient Advice | This medication is a corticosteroid injected directly into the affected area to reduce inflammation. · Do not receive live vaccines (e.g., nasal flu vaccine, MMR, varicella) while on this treatment. · Report signs of infection (fever, redness, swelling) or injection site pain that worsens after injection. · Avoid strenuous activity or overuse of the treated joint for 24-48 hours after injection. · Notify your doctor if you have diabetes (may raise blood sugar), tuberculosis, herpes, or fungal infections. · Do not stop this medication abruptly if used for a long time; tapering is required. · Inform your healthcare provider of all medications you take, including NSAIDs, anticoagulants, and diabetes medicines. |